Carbidopa/levodopa controlled-release - Depomed

Drug Profile

Carbidopa/levodopa controlled-release - Depomed

Alternative Names: DM-1992

Latest Information Update: 09 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Depomed
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Parkinson's disease

Most Recent Events

  • 13 Nov 2012 Depomed completes a phase II trial in Parkinson's disease in the USA (NCT01515410)
  • 09 Nov 2012 Interim efficacy and safety data from a phase II trial in Parkinson's disease released by Depomed
  • 05 Jul 2012 Depomed completes enrolment in its phase II trial in Parkinson's disease in the US (NCT01515410)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top